Prio
Sign up
-
March 9, 2020
Published: March 9, 2020
Top stories
Global report – May 12, 2026
Bristol Myers Squibb and Hengrui Pharma announce strategic agreements
The companies have entered into global strategic collaboration and license agreements to advance a portfolio of 13 early stage programs in oncology, hematology and immunology.
Pharma Business – May 12, 2026
Bavarian Nordic awarded contract options from US Government
The Center for the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), has exercised additional options valued at USD 97 million under the existing contract to supply a freeze-dried formulation of JYNNEOS smallpox vaccine.
Clinical Trials – May 12, 2026
AnaCardio announces Phase 1b/2a results
AnaCardio has announced detailed results from its Phase 1b/2a GOAL-HF1 study evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF).
Biotech Business – May 11, 2026
FDA extends sBLA review of Leqembi Iqlik
BioArctic’s partner Eisai has announced that the FDA has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection, also known as Leqembi Iqlik, as a starting dose for the treatment of early Alzheimer’s disease.
Follow NLS news
